.4%, PAD
14.9%, AAA 6.38%

Guideline-oriented medical
treatment, not speciÔ¨Åed

Walker et al,3 1995
(ACAS trial)

(A) 834
(B) 825

NR

(A) 66
(B) 66

NR

(A) CAD 69%, HTN 64%,
cancer 10%, DM 2